Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Obtaining data on efficacy (e.g. complete ST-segment resolution) depending on the time of treatment initiation and safety of prehospital and early hospital thrombolysis with Metalyse® in a real life setting outside clinical trials.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Tenecteplase; Tissue Plasminogen Activator

Criteria

Inclusion criteria:

• Male and female patient with suspected myocardial infarction, e.g. during transportation to the hospital by ambulance. No patient younger than 18 years.

• Possibility of obtaining relevant information concerning indication or contraindication of thrombolysis in each patient

• Typical chest pain with a duration of more than 30 minutes

• Definite infarction signs in a 12-lead-ECG with ST-elevation > 0.1 millivolt (mV) in > 2 leads or recent left bundle branch block with typical clinical signs

• Symptom onset <= 6 hours

Exclusion criteria:

• Patients older than 75 years (exception: patients appear much younger)

• Low body weight

• No persons under 18

• contraindications according to summary of product characteristics (SPC) for Metalyse